The European Commission has approved Merck's (MRK) KEYTRUDA plus Paclitaxel with or without Bevacizumab for the treatment of adults with PD-L1 platinum-resistant recurrent ovarian cancer

The European Commission's approval for Merck's KEYTRUDA treatment marks a significant milestone for the company, potentially boosting its revenues in the oncology market.

Newsquawk StaffPublished On the live feed at 6 more headlines followed before this page went public
Newsquawk headlinesUTC

Merck (MRK) starts phase 2b/3 trial evaluating Tiespectus for the treatment of neovascular age-related macular degeneration

Russia is likely to experience oil production cuts following drone attacks, Reuters reports citing sources

The European Commission has approved Merck's (MRK) KEYTRUDA plus Paclitaxel with or without Bevacizumab for the treatment of adults with PD-L1 platinum-resistant recurrent ovarian cancer

OPEC+ is likely to consider a further oil output quota hike at its Sunday meeting to prepare for any easing of Hormuz export constraints, Reuters reports citing sources

The sound of explosions in Karaj and Tehran, Mehr News reports

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

This development could enhance investor sentiment towards Merck and the broader pharmaceutical sector, particularly as it addresses an unmet medical need in recurrent ovarian cancer patients. Market participants may also be evaluating implications for Merck's competitiveness against other players in the oncology space.

Related headlines

The whole workspace, free to try.

Try it free